PubRank

Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia

Clinical Trial ID NCT00545974

PubWeight™ 9.36‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00545974

Top papers

Rank Title Journal Year PubWeight™‹?›
1 "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 301.74
2 The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993 47.72
3 Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998 26.77
4 A new rating scale for Alzheimer's disease. Am J Psychiatry 1984 15.16
5 Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003 6.79
6 Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994 6.77
7 Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004 6.74
8 The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997 6.33
9 Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006 5.14
10 Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006 4.07
11 Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc 1992 3.66
12 Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006 3.60
13 Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006 3.58
14 The evolution and pathology of frontotemporal dementia. Brain 2005 3.46
15 Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci 1997 2.23
16 NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008 2.13
17 Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013 1.84
18 Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999 1.74
19 A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006 1.62
20 Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002 1.57
21 Clinical features of frontotemporal dementia. Alzheimer Dis Assoc Disord 2005 1.48
22 NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci U S A 2006 1.44
23 Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007 1.43
24 Performance-Based instrument to assess functional capacity in dementia: The Texas Functional Living Scale. Neuropsychiatry Neuropsychol Behav Neurol 2001 1.37
25 A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002 1.29
26 The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement 2012 1.14
27 Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2004 1.11
28 Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. Expert Rev Neurother 2011 0.91
29 Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry 2003 0.90
30 Ecological validity and neuroanatomical correlates of the NIH EXAMINER executive composite score. J Int Neuropsychol Soc 2013 0.88
31 Diagnosis and management of behavioral issues in frontotemporal dementia. Curr Neurol Neurosci Rep 2012 0.86
32 Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets 2008 0.80
33 Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective. J Nucleic Acids 2013 0.75
Next 100